BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17211705)

  • 21. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.
    Furuta T; Ohashi K; Kosuge K; Zhao XJ; Takashima M; Kimura M; Nishimoto M; Hanai H; Kaneko E; Ishizaki T
    Clin Pharmacol Ther; 1999 May; 65(5):552-61. PubMed ID: 10340921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism.
    Sagar M; Tybring G; Dahl ML; Bertilsson L; Seensalu R
    Gastroenterology; 2000 Sep; 119(3):670-6. PubMed ID: 10982760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine.
    Uotani T; Sugimoto M; Nishino M; Ichikawa H; Sahara S; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Watanabe H; Miyajima H; Furuta T
    J Clin Pharmacol; 2014 Aug; 54(8):858-64. PubMed ID: 24615745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
    Kita T; Sakaeda T; Aoyama N; Sakai T; Kawahara Y; Kasuga M; Okumura K
    Biol Pharm Bull; 2002 Jul; 25(7):923-7. PubMed ID: 12132671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers.
    Nishino M; Sugimoto M; Kodaira C; Yamade M; Uotani T; Shirai N; Ikuma M; Tanaka T; Sugimura H; Hishida A; Furuta T
    J Clin Pharmacol; 2011 Jul; 51(7):1079-86. PubMed ID: 20663999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.
    Yang JC; Wang HL; Chern HD; Shun CT; Lin BR; Lin CJ; Wang TH
    Pharmacotherapy; 2011 Mar; 31(3):227-38. PubMed ID: 21361732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects.
    Hu YM; Xu JM; Mei Q; Xu XH; Xu SY
    Acta Pharmacol Sin; 2005 Mar; 26(3):384-8. PubMed ID: 15715938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability.
    Kita T; Tanigawara Y; Aoyama N; Hohda T; Saijoh Y; Komada F; Sakaeda T; Okumura K; Sakai T; Kasuga M
    Pharm Res; 2001 May; 18(5):615-21. PubMed ID: 11465416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease].
    Sohn YH; Lee WS; Park CH; Joo YE; Kim HS; Choi SK; Rew JS; Kim SJ
    Korean J Gastroenterol; 2006 Sep; 48(3):162-71. PubMed ID: 17047431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes.
    Hayato S; Hasegawa S; Hojo S; Okawa H; Abe H; Sugisaki N; Munesue M; Horai Y; Ohnishi A
    Eur J Clin Pharmacol; 2012 May; 68(5):579-88. PubMed ID: 22108775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping.
    Miehlke S; Löbe S; Madisch A; Kuhlisch E; Laass M; Grossmann D; Knoth H; Morgner A; Labenz J
    Aliment Pharmacol Ther; 2011 Feb; 33(4):471-6. PubMed ID: 21175704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment.
    Miner PB; Allgood LD; Grender JM
    Aliment Pharmacol Ther; 2007 Jan; 25(1):103-9. PubMed ID: 17229225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between the acid-inhibitory effects of two proton pump inhibitors and CYP2C19 genotype in Japanese subjects: a randomized two-way crossover study.
    Furuta K; Adachi K; Ohara S; Morita T; Tanimura T; Koshino K; Kinoshita Y
    J Int Med Res; 2010; 38(4):1473-83. PubMed ID: 20926021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2-receptor antagonist.
    Shimatani T; Inoue M; Kuroiwa T; Horikawa Y; Mieno H; Nakamura M
    Aliment Pharmacol Ther; 2003 Dec; 18(11-12):1149-57. PubMed ID: 14653835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generic versus brand-name medicinal products: are they really interchangeable?
    Motola D; De Ponti F
    Dig Liver Dis; 2006 Aug; 38(8):560-2. PubMed ID: 16731062
    [No Abstract]   [Full Text] [Related]  

  • 36. Omeprazole disposition in children following single-dose administration.
    Kearns GL; Andersson T; James LP; Gaedigk A; Kraynak RA; Abdel-Rahman SM; Ramabadran K; van den Anker JN
    J Clin Pharmacol; 2003 Aug; 43(8):840-8. PubMed ID: 12953341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.
    Shirai N; Furuta T; Moriyama Y; Okochi H; Kobayashi K; Takashima M; Xiao F; Kosuge K; Nakagawa K; Hanai H; Chiba K; Ohashi K; Ishizaki T
    Aliment Pharmacol Ther; 2001 Dec; 15(12):1929-37. PubMed ID: 11736724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.
    Okudaira K; Furuta T; Shirai N; Sugimoto M; Miura S
    Aliment Pharmacol Ther; 2005 Feb; 21(4):491-7. PubMed ID: 15710002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
    Adachi K; Katsube T; Kawamura A; Takashima T; Yuki M; Amano K; Ishihara S; Fukuda R; Watanabe M; Kinoshita Y
    Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans.
    Hu YM; Mei Q; Xu XH; Hu XP; Hu NZ; Xu JM
    World J Gastroenterol; 2006 Aug; 12(29):4750-3. PubMed ID: 16937451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.